Kate, if one had to guess it would be that there are a great number of MSers interested in BG-12. Its effectiveness and safety profile both appear to excel the crab drugs. And since it is not an immunosuppressant many may prefer it to Gilyena, especially since it has a solid safety profile compared with that drug, also.
October will be about 10 months from when Biogen submitted BG-12 for FDA approval, so we may see approval during Oct or soon after, 10 months being a roughly average time before an FDA approval.
Toss-up whether it will be taken twice or three times a day. Twice would be more convenient for patients, but just a guess.
IF BG-12 works as trials indicate, the popularity of CRAB drugs may quickly fade. Considering no needles, no flu-like symptoms, safety, and effectiveness Biogen may have a huge winner. But cost will be a factor.
I believe they intend to price BG-12 similar to Tysabri and Gilyena, both of which are just under $4000 a month, I believe. I could be wrong, JMHO.
For MSers who might be thinking of doing an end around attempting to source dimethyl fumarate from the German company who makes fumaderm for psoriasis, I hate to tell you but Biogen bought that German company in 2006. Evidently, Biogen has been preparing to reap maximum benefit from BG-12 for several years. They may be right because a safe and effective oral med is likely to be very, very appealing.
A2, Ann Arbor? “Mad scientists” all over the place, Kate. Love that photo!
October will be about 10 months from when Biogen submitted BG-12 for FDA approval, so we may see approval during Oct or soon after, 10 months being a roughly average time before an FDA approval.
Toss-up whether it will be taken twice or three times a day. Twice would be more convenient for patients, but just a guess.
IF BG-12 works as trials indicate, the popularity of CRAB drugs may quickly fade. Considering no needles, no flu-like symptoms, safety, and effectiveness Biogen may have a huge winner. But cost will be a factor.
I believe they intend to price BG-12 similar to Tysabri and Gilyena, both of which are just under $4000 a month, I believe. I could be wrong, JMHO.
For MSers who might be thinking of doing an end around attempting to source dimethyl fumarate from the German company who makes fumaderm for psoriasis, I hate to tell you but Biogen bought that German company in 2006. Evidently, Biogen has been preparing to reap maximum benefit from BG-12 for several years. They may be right because a safe and effective oral med is likely to be very, very appealing.
A2, Ann Arbor? “Mad scientists” all over the place, Kate. Love that photo!
Comment